

DAFTAR PUSTAKA

- Aibani, N., Rai, R., Patel, P., Cuddihy, G., Wasan, E.K., 2021. Chitosan nanoparticles at the biological interface: implications for drug delivery. *Pharmaceutics* 13. doi: 10.3390/pharmaceutics13101686.
- Aka, J.A., Lin, S.X., 2012. Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7. *PLoS One* 7: 1–9. doi:10.1371/journal.pone.0031532.
- Anwar, S.L., Sari, D.N.I., Kartika, A.I., Fitria, M.S., Tanjung, D.S., Rakhmina, D., Wardana, T *et al.*, 2019. Upregulation of circulating MiR-21 expression as a potential biomarker for therapeutic monitoring and clinical outcome in breast cancer. *Asian Pacific J. Cancer Prev.* 20: 1223–1228. doi:10.31557/APJCP.2019.20.4.1223.
- Aure, M.R., Fleischer, T., Bjørklund, S., Ankill, J., Castro-Mondragon, J.A., Børresen-Dale, A.L., Tost, J *et al.*, 2021. Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer. *Genome Med.* 13(72). doi:10.1186/s13073-021-00880-4.
- Bahuguna, A., Khan, I., Bajpai, V.K., Kang, S.C., 2017. MTT assay to evaluate the cytotoxic potential of a drug. *Bangladesh J. Pharmacol.* 12: 115–118. doi:10.3329/bjp.v12i2.30892.
- Bangun, H., Tandiono, S., Arianto, A., 2018. Preparation and evaluation of chitosan-tripolyphosphate nanoparticles suspension as an antibacterial agent. *J. Appl. Pharm. Sci.* 8: 147–156. doi:10.7324/JAPS.2018.81217
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 68: 394–424. doi:10.3322/caac.21492.
- Brooks, E.A., Galarza, S., Gencoglu, M.F., Chase Cornelison, R., Munson, J.M., Peyton, S.R., 2019. Applicability of drug response metrics for cancer studies using biomaterials. *Philos. Trans. R. Soc. B Biol. Sci.* 374. doi:10.1098/rstb.2018.0226.
- Cai, W.Y., Wei, T.Z., Luo, Q.C., Wu, Q.W., Liu, Q.F., Yang, M., Ye, G.D *et al.*, 2013. The wnt- β -catenin pathway represses let-7 microrna expression through transactivation of Lin28 to augment breast cancer stem cell expansion. *J. Cell Sci.* 126: 2877–2889. doi:10.1242/jcs.123810.
- Cao, Y., Tan, Y.F., Wong, Y.S., Liew, M.W.J., Venkatraman, S., 2019. Recent advances in chitosan-based carriers for gene delivery. *Mar. Drugs* 17. doi:10.3390/md17060381.
- Carrillo, C., Suñé, J.M., Pérez-Lozano, P., García-Montoya, E., Sarrate, R., Fàbregas, A., Miñarro, M *et al.*, 2014. Chitosan nanoparticles as non-viral gene delivery systems: Determination of loading efficiency. *Biomed. Pharmacother.* 68: 775–783. doi:10.1016/j.biopha.2014.07.009.
- Chaudhary, V., Jangra, S., Yadav, N.R., 2018. Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection. *J. Nanobiotechnology* 16: 1–18. doi:10.1186/s12951-018-0368-8.
- Chen, H., Liu, H., Qing, G., 2018. Targeting oncogenic Myc as a strategy for cancer

- treatment. *Signal Transduct. Target. Ther.* 3: 1–7. doi:10.1038/s41392-018-0008-7.
- Chen, P.S., Su, J.L., Hung, M.C., 2012. Dysregulation of MicroRNAs in cancer. *J. Biomed. Sci.* 19: 1–8. doi:10.1186/1423-0127-19-90.
- Chen, R., Guo, S., Yang, C., Sun, L., Zong, B., Li, K., Liu, L *et al.*, 2020. Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer. *Int. J. Oncol.* 56: 932–944. doi:10.3892/ijo.2020.4987.
- Chirshhev, E., Oberg, K.C., Ioffe, Y.J., Unternaehrer, J.J., 2019. Let - 7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. *Clin. Transl. Med.* 8(24). doi:10.1186/s40169-019-0240-y.
- Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A *et al.*, 2018. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. *Pharmaceutics* 10: 1–17. doi:10.3390/pharmaceutics10020057.
- Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X *et al.*, 2014. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. *Biomaterials* 35: 4333–4344. doi:10.1016/j.biomaterials.2014.02.006.
- Denizli, M., Aslan, B., Mangala, L.S., Jiang, D., Rodriguez-Aguayo, C., Lopez-Berestein, G., Sood, A.K., 2017. Chitosan Nanoparticles for miRNA Delivery, in: Bindewald, E., Shapiro, B.A. (Ed.), *Methods in Molecular Biology*. Springer New York, New York, NY, hal. 219–230. doi:10.1007/978-1-4939-7138-1_14.
- Denkiewicz, M., Saha, I., Rakshit, S., Sarkar, J.P., Plewczynski, D., 2019. Identification of breast cancer subtype specific micromnas using survival analysis to find their role in transcriptomic regulation. *Front. Genet.* 10: 1–19. doi:10.3389/fgene.2019.01047.
- Di Leva, G., Gasparini, P., Piovan, C., Nganheu, A., Garofalo, M., Taccioli, C., Iorio, M. V *et al.*, 2010. MicroRNA cluster 221-222 and estrogen receptor α interactions in breast cancer. *J. Natl. Cancer Inst.* 102: 706–721. doi:10.1093/jnci/djq102.
- Ding, L., Gu, H., Xiong, X., Ao, H., Cao, J., Lin, W., Yu, M *et al.*, 2019. MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer. *Cells* 8. doi:10.3390/cells8121492.
- Du, J., Fan, J.J., Dong, C., Li, H.T., Ma, B.L., 2019. Inhibition effect of exosomes-mediated Let-7a on the development and metastasis of Triple negative breast cancer by down-regulating the expression of c-Myc. *Eur. Rev. Med. Pharmacol. Sci.* 23: 5301–5314. doi:10.26355/eurrev_201906_18197.
- Fadhil, R.S., Wei, M.Q., Nikolarakos, D., Good, D., Nair, R.G., 2020. Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic bio-markers for head and neck squamous cell carcinoma. *PLoS One* 15: 1–12. doi:10.1371/journal.pone.0221779.
- Fallah, Y., Brundage, J., Allegakoen, P., Shajahan-Haq, A.N., 2017. MYC-Driven pathways in breast cancer subtypes. *Biomolecules* 7: 1–6. doi:10.3390/

biom7030053.

- Fan, W., Chang, J., Fu, P., 2015. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. *Future Med. Chem.* 7: 1511–1519. doi:10.4155/fmc.15.93.
- Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X *et al.*, 2018. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis.* 5: 77–106. doi:10.1016/j.gendis.2018.05.001.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M *et al.*, 2015. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer* 136: E359–E386. doi:10.1002/ijc.29210.
- Fröhlich, E., 2012. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. *Int. J. Nanomedicine* 7: 5577–5591. doi:10.2147/IJN.S36111.
- Gao, S., Tian, H., Guo, Y., Li, Y., Guo, Z., Zhu, X., Chen, X., 2015. miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy. *Acta Biomater.* 25: 184–193. doi:10.1016/j.actbio.2015.07.020.
- Ghoshal, A., Shankar, R., Bagchi, S., Grama, A., Chatterji, S., 2015. MicroRNA target prediction using thermodynamic and sequence curves. *BMC Genomics* 16: 1–21. doi:10.1186/s12864-015-1933-2.
- GLOBOCAN, 2018. Cancer Incident in Indonesia. *Int. Agency Res. Cancer* 256: 1–2.
- GLOBOCAN, 2020. Cancer Incident in Indonesia. *Int. Agency Res. Cancer* 858: 1–2.
- Griffiths, D., Bernt, W., Hole, P., Smith, J., Malloy, A., Carr, B., 2011. Zeta potential measurement of nanoparticles by nanoparticle tracking analysis (NTA). *Tech. Proc. 2011 NSTI Nanotechnol. Conf. Expo, NSTI-Nanotech 2011* 1: 4–7.
- Guo, H., Li, F., Qiu, H., Liu, J., Qin, S., Hou, Y., Wang, C., 2020. Preparation and Characterization of Chitosan Nanoparticles for Chemotherapy of Melanoma Through Enhancing Tumor Penetration. *Front. Pharmacol.* 11: 1–8. doi:10.3389/fphar.2020.00317.
- Ha, M., Kim, V.N., 2014. Regulation of microRNA biogenesis. *Nat. Rev. Mol. Cell Biol.* 15: 509–524. doi:10.1038/nrm3838.
- Hannafon, B.N., Cai, A., Calloway, C.L., Xu, Y.-F., Zhang, R., Fung, K.-M., Ding, W.-Q., 2019. miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study. *BMC Cancer* 19: 642. doi:10.1186/s12885-019-5839-2.
- Haque, M.M., Desai, K. V., 2019. Pathways to Endocrine Therapy Resistance in Breast Cancer. *Front. Endocrinol. (Lausanne)*. 10: 1–7. doi:10.3389/fendo.2019.00573.
- He, X.Y., Chen, J.X., Zhang, Z., Li, C.L., Peng, Q. Le, Peng, H.M., 2010. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. *J. Cancer Res. Clin. Oncol.* 136: 1023–1028.

doi:10.1007/s00432-009-0747-5.

- Heidari, R., Khosravian, P., Mirzaei, S.A., Elahian, F., 2021. siRNA delivery using intelligent chitosan-capped mesoporous silica nanoparticles for overcoming multidrug resistance in malignant carcinoma cells. *Sci. Rep.* 11: 1–14. doi:10.1038/s41598-021-00085-0.
- Herdiana, Y., Wathoni, N., Shamsuddin, S., Joni, I.M., Muchtaridi, M., 2021. Chitosan-based nanoparticles of targeted drug delivery system in breast cancer treatment. *Polymers (Basel)*. 13. doi:10.3390/polym13111717.
- Hong, D.S., Kang, Y.K., Borad, M., Sachdev, J., Ejadi, S., Lim, H.Y., Brenner, A.J *et al.*, 2020. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. *Br. J. Cancer* 122: 1630–1637. doi:10.1038/s41416-020-0802-1.
- Huang, Y., Zou, Q., Song, H., Song, F., Wang, L., Zhang, G., Shen, X., 2010. A study of miRNAs targets prediction and experimental validation. *Protein Cell* 1: 979–986. doi:10.1007/s13238-010-0129-4.
- Ivanova, A., Xiao, C., 2013. Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs. *Pharm. Stat.* 12: 309–314. doi:10.1002/pst.1585.
- Jhaveri, J., Raichura, Z., Khan, T., Momin, M., Omri, A., 2021. Chitosan nanoparticles-insight into properties, functionalization and applications in drug delivery and theranostics. *Molecules* 26. doi:10.3390/molecules26020272.
- Jin, B., Wang, W., Meng, X. xin, Du, G., Li, J., Zhang, S. zhe, Zhou, B. hai, Fu, Z. hao, 2016. Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway. *BMC Cancer* 16: 1–10. doi:10.1186/s12885-016-2904-y.
- Jreyssaty, C., Shi, Q., Wang, H., Qiu, X., Winnik, F.M., Zhang, X., Dai, K *et al.*, 2012. Efficient Nonviral Gene Therapy Using Folate-Targeted Chitosan-DNA Nanoparticles In Vitro. *ISRN Pharm.* 2012, 1–9. doi:10.5402/2012/369270.
- Kaboli, P.J., Rahmat, A., Ismail, P., Ling, K.H., 2015. MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. *Pharmacol. Res.* 97: 104–121. doi:10.1016/j.phrs.2015.04.015.
- Kamran, M., 2021. Fuel cell, in: *Renewable Energy Conversion Systems*. Elsevier, hal. 221–242. doi:10.1016/B978-0-12-823538-6.00005-1
- Khalighfard, S., Alizadeh, A.M., Irani, S., Omranipour, R., 2018. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. *Sci. Rep.* 8: 1–11. doi:10.1038/s41598-018-36321-3.
- Kouchak, M., Avadi, M., Abbaspour, M., Jahangiri, A., Boldaji, S.K., 2012. Effect of different molecular weights of chitosan on preparation and characterization of insulin loaded nanoparticles by ion gelation method. *Int. J. Drug Dev. Res.* 4: 272–277.
- Krishnamurthy, N., Kurzrock, R., 2018. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. *Cancer Treat. Rev.* 62: 50–60. doi:10.1016/j.ctrv.2017.11.002.

- Kudela, E., Samec, M., Koklesova, L., Liskova, A., Kubatka, P., Kozubik, E., Rokos, T *et al.*, 2020. Mirna expression profiles in luminal a breast cancer—implications in biology, prognosis, and prediction of response to hormonal treatment. *Int. J. Mol. Sci.* 21: 1–20. doi:10.3390/ijms21207691.
- Kumar, A., Dixit, C.K., 2017. Methods for characterization of nanoparticles. *Adv. Nanomedicine Deliv. Ther. Nucleic Acids* 1: 44–58. doi:10.1016/B978-0-08-100557-6.00003-1.
- Kurozumi, S., Yamaguchi, Y., Kurosumi, M., Ohira, M., Matsumoto, H., Horiguchi, J., 2017. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. *J. Hum. Genet.* 62: 15–24. doi:10.1038/jhg.2016.89.
- Lal, A., Navarro, F., Maher, C.A., Maliszewski, L.E., Yan, N., O'Day, E., Chowdhury, D *et al.*, 2009. miR-24 Inhibits Cell Proliferation by Targeting E2F2, MYC, and Other Cell-Cycle Genes via Binding to “Seedless” 3'UTR MicroRNA Recognition Elements. *Mol. Cell* 35, 610–625. doi:10.1016/j.molcel.2009.08.020
- Lara-Velazquez, M., Alkharboosh, R., Norton, E.S., Ramirez-Loera, C., Freeman, W.D., Guerrero-Cazares, H., Forte, A.J *et al.*, 2020. Chitosan-Based Non-viral Gene and Drug Delivery Systems for Brain Cancer. *Front. Neurol.* 11. doi:10.3389/fneur.2020.00740.
- Lee, S.W.L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R.D., Mattu, C *et al.*, 2019. MicroRNA delivery through nanoparticles. *J. Control. Release* 313: 80–95. doi:10.1016/j.jconrel.2019.10.007.
- Li, D., Xia, H., Li, Z.Y., Hua, L., Li, L., 2015. Identification of novel breast cancer subtype-specific biomarkers by integrating genomics analysis of DNA copy number aberrations and miRNA-mRNA dual expression profiling. *Biomed Res. Int.* 2015. doi:10.1155/2015/746970.
- Li, F., Wang, F., Zhu, C., Wei, Q., Zhang, T., Zhou, Y.L., 2018. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker. *Int. J. Nanomedicine* 13: 2295–2307. doi:10.2147/IJN.S157805.
- Li, X., Ding, R., Han, Z., Ma, Z., Wang, Y., 2017. Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells. *Biomed. Pharmacother.* 96: 434–442. doi:10.1016/j.biopha.2017.09.149.
- Lin, B., Chen, H., Liang, D., Lin, W., Qi, X., Liu, H., Deng, X., 2019. Acidic pH and High-H₂O₂ Dual Tumor Microenvironment-Responsive Nanocatalytic Graphene Oxide for Cancer Selective Therapy and Recognition. *ACS Appl. Mater. Interfaces* 11: 11157–11166. doi:10.1021/acsami.8b22487.
- Ling, R., Zhou, Y., Zhou, L., Dai, D., Wu, D., Mi, L., Mao, C *et al.*, 2018. Lin28/microRNA-let-7a promotes metastasis under circumstances of hyperactive Wnt-signaling in esophageal squamous cell carcinoma. *Mol. Med. Rep.* 17: 5265–5271. doi:10.3892/mmr.2018.8548.
- Liu, C., Rennie, W.A., Mallick, B., Kanoria, S., Long, D., Wolenc, A., Carmack, C.S *et al.*, 2014. MicroRNA binding sites in *C. elegans* 3' UTRs. *RNA Biol.* 11: 693–701. doi:10.4161/rna.28868.

- Liu, K., Zhang, C., Li, T., Ding, Y., Tu, T., Zhou, F., Qi, W *et al.*, 2015. Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1. *Int. J. Oncol.* 46: 2526–2534. doi:10.3892/ijo.2015.2949.
- Liu, Y., Yin, B., Zhang, C., Zhou, L., Fan, J., 2012. Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc. *Biochem. Biophys. Res. Commun.* 417: 371–375. doi:10.1016/j.bbrc.2011.11.119.
- Loginov, V.I., Burdennyy, A.M., Pronina, I. V., Khokonova, V. V., Kurevljov, S. V., Kazubskaya, T.P., Kushlinskii, N.E *et al.*, 2016. Novel miRNA genes hypermethylated in breast cancer. *Mol. Biol.* 50: 705–709. doi:10.1134/S0026893316050101.
- Loh, H.Y., Norman, B.P., Lai, K.S., Rahman, N.M.A.N.A., Alitheen, N.B.M., Osman, M.A., 2019. The regulatory role of microRNAs in breast cancer. *Int. J. Mol. Sci.* 20: 1–27. doi:10.3390/ijms20194940.
- Luo, C., Zhang, J., Zhang, Y., Zhang, X., Chen, Y., Fan, W., 2020. Low expression of miR-let-7a promotes cell growth and invasion through the regulation of c-Myc in oral squamous cell carcinoma. *Cell Cycle* 19: 1983–1993. doi:10.1080/15384101.2020.1786633.
- Lv, K., Liu, L., Wang, L., Yu, J., Liu, X., Cheng, Y., Dong, M *et al.*, 2012. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. *PLoS One* 7: 1–8. doi:10.1371/journal.pone.0040008.
- Ma, Y., Shen, N., Wicha, M.S., Luo, M., 2021. The roles of the let-7 family of micrnas in the regulation of cancer stemness. *Cells* 10: 1–20. doi:10.3390/cells10092415.
- Mansoori, B., Mohammadi, A., Shirjang, S., Baghbani, E., Baradaran, B., 2016. Micro RNA 34a and let-7a expression in human breast cancers is associated with apoptotic expression genes. *Asian Pacific J. Cancer Prev.* 17: 1887–1890. doi:10.7314/APJCP.2016.17.4.1887.
- Mao, S., Sun, W., Kissel, T., 2010. Chitosan-based formulations for delivery of DNA and siRNA. *Adv. Drug Deliv. Rev.* 62: 12–27. doi:10.1016/j.addr.2009.08.004.
- Mardliyati, E., Muttaqien, S. El, Setyawati, D.R., 2012. Sintesis nanopartikel kitosan- trypoly phosphate dengan metode gelasi ionik : pengaruh konsentrasi dan rasio volume terhadap karakteristik partikel. *Pros. Pertem. Ilm. Ilmu Pengetah. dan Teknol. Bahan* 90–93.
- Marques, M.M., Evangelista, A.F., Macedo, T., Vieira, R.A. da C., Scapulatempo-Neto, C., Reis, R.M., Carvalho, A.L *et al.*, 2018. Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer. *Clinics* 73: 1–6. doi:10.6061/clinics/2018/e184.
- Masoud, V., Pagès, G., 2017. Targeted therapies in breast cancer: New challenges to fight against resistance. *World J. Clin. Oncol.* 8: 120–134. doi:10.5306/wjco.v8.i2.120.
- Mohammadpour Dounighi, N., Damavandi, M., Zolfagharian, H., Moradi, S., 2012. Preparing and characterizing chitosan nanoparticles containing hemiscorpius lepturus scorpion venom as an antigen delivery system. *Arch. Razi Inst.* 67: 145–153.
- Mulrane, L., McGee, S.F., Gallagher, W.M., O'Connor, D.P., 2013. miRNA

- dysregulation in breast cancer. *Cancer Res.* 73: 6554–6562. doi:10.1158/0008-5472.CAN-13-1841.
- Nassir, A.M., Ibrahim, I.A.A., Md, S., Waris, M., Tanuja, Ain, M.R., Ahmad, I., Shahzad, N., 2019. Surface functionalized folate targeted oleuropein nano-liposomes for prostate tumor targeting: In vitro and in vivo activity. *Life Sci.* 220: 136–146. doi:10.1016/j.lfs.2019.01.053.
- Nisa, U., Astuti, I., Martien, R., Maulana, D.R., Ysrafil., 2020. Chitosan Nanoparticle as a Delivery System of miRNA 217 for Suppressing Hepatocellular Carcinoma Progressivity by Targeting AEG-1/P53, in: *Proceedings of the 1st Jenderal Soedirman International Medical Conference* in conjunction with the 5th Annual Scientific Meeting (Temilnas) Consortium of Biomedical Science Indonesia. SCITEPRESS - Science and Technology Publications, hal. 131–138. doi:10.5220/0010489001310138.
- O'Brien, J., Hayder, H., Zayed, Y., Peng, C., 2018. Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Front. Endocrinol. (Lausanne)*. 9: 1–12. doi:10.3389/fendo.2018.00402.
- O'Neill, C.P., Dwyer, R.M., 2020. Nanoparticle-Based Delivery of Tumor Suppressor microRNA for Cancer Therapy. *Cells* 9: 521. doi:10.3390/cells9020521.
- Othman, N., Masarudin, M.J., Kuen, C.Y., Dasuan, N.A., Abdullah, L.C., Jamil, S.N.A.M., 2018. Synthesis and optimization of chitosan nanoparticles loaded with l-ascorbic acid and thymoquinone. *Nanomaterials* 8. doi:10.3390/nano8110920.
- Pedroso-Santana, S., Fleitas-Salazar, N., 2020. Ionotropic gelation method in the synthesis of nanoparticles/microparticles for biomedical purposes. *Polym. Int.* 69: 443–447. doi:10.1002/pi.5970.
- Peng, Y., Croce, C.M., 2016. The role of microRNAs in human cancer. *Signal Transduct. Target. Ther.* 1. doi:10.1038/sigtrans.2015.4.
- Pinho, F.G., Frampton, A.E., Nunes, J., Krell, J., Alshaker, H., Jacob, J., Pellegrino, L *et al.*, 2013. Downregulation of microRNA-515-5p by the estrogen receptor modulates Sphingosine kinase 1 and breast cancer cell proliferation. *Cancer Res.* 73: 5936–5948. doi:10.1158/0008-5472.CAN-13-0158.
- Prat, A., Guo, H., Ganesan, P., Parker, J.S., Gao, M., Moulder, S., Karginova, O *et al.*, 2010. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res.* 12: 68–86.
- Ralston, S.H., Penman, I., Strachan, M., Hobson, R., 2018. *Davidson 's Principles and Practice of Medicine*. hal: 13-36. Elsevier, New York (US).
- Ramchandani, D., Lee, S.K., Yomtoubian, S., Han, M.S., Tung, C.-H., Mittal, V., 2019. Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis. *Mol. Cancer Ther.* 18: 579–591. doi:10.1158/1535-7163.MCT-18-0702.
- Rennie, W., Kanoria, S., Liu, C., Mallick, B., Long, D., Wolenc, A., Carmack, C.S *et al.*, 2016. STarMirDB: A database of microRNA binding sites. *RNA Biol.* 13: 554–560. doi:10.1080/15476286.2016.1182279
- Riolo, G., Cantara, S., Marzocchi, C., Ricci, C., 2021. miRNA targets: From prediction tools to experimental validation. *Methods Protoc.* 4: 1–20.

doi:10.3390/mps4010001.

- Rizkita, L.D., Ysrafil, Martien, R., Astuti, I., 2021. Chitosan nanoparticles mediated delivery of MIR-106B-5P to breast cancer cell lines MCF-7 and T47D. *Int. J. Appl. Pharm.* 13: 129–134. doi:10.22159/ijap.2021v13i1.39749.
- Ruzzo, A., Graziano, F., Vincenzi, B., Canestrari, E., Perrone, G., Galluccio, N., Catalano, V *et al.*, 2012. High Let-7a MicroRNA Levels in KRAS -Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. *Oncologist* 17: 823–829. doi:10.1634/theoncologist.2012-0081.
- Santos-Carballal, B., Aaldering, L.J., Ritzefeld, M., Pereira, S., Sewald, N., Moerschbacher, B.M., Götte, M *et al.*, 2015. Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. *Sci. Rep.* 5: 1–15. doi:10.1038/srep13567.
- Sauter, E.R., 2017. Reliable Biomarkers to Identify New and Recurrent Cancer. *Eur. J. Breast Heal.* 13: 162–167. doi:10.5152/ejbh.2017.3635.
- Shams, R., Aghdaei, H.A., Behmanesh, A., Sadeghi, A., Zali, M., Salari, S., Padrón, J.M., 2020. Micrnas targeting myc expression: Trace of hope for pancreatic cancer therapy. a systematic review. *Cancer Manag. Res.* 12: 2393–2404. doi:10.2147/CMAR.S245872.
- Shao, X.R., Wei, X.Q., Song, X., Hao, L.Y., Cai, X.X., Zhang, Z.R., Peng, Q *et al.*, 2015. Independent effect of polymeric nanoparticle zeta potential/surface charge, on their cytotoxicity and affinity to cells. *Cell Prolif.* 48: 465–474. doi:10.1111/cpr.12192.
- Shu, Y., Wu, K., Zeng, Z., Huang, S., Ji, X., Yuan, C., Zhang, L *et al.*, 2018. A Simplified System to Express Circularized Inhibitors of miRNA for Stable and Potent Suppression of miRNA Functions. *Mol. Ther. - Nucleic Acids* 13: 556–567. doi:10.1016/j.omtn.2018.09.025.
- Singh, R., Mo, Y.Y., 2013. Role of microRNAs in breast cancer. *Cancer Biol. Ther.* 14: 201–212. doi:10.4161/cbt.23296.
- Smith, S.A., Selby, L.I., Johnston, A.P.R., Such, G.K., 2019. The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular Delivery. *Bioconjug. Chem.* 30: 263–272. doi:10.1021/acs.bioconjchem.8b00732.
- Søkilde, R., Persson, H., Ehinger, A., Pirona, A.C., Fernö, M., Hegardt, C., Larsson, C *et al.*, 2019. Refinement of breast cancer molecular classification by miRNA expression profiles. *BMC Genomics* 20: 1–12. doi:10.1186/s12864-019-5887-7.
- Sun, J., Kim, D.H., Guo, Y., Teng, Z., Li, Y., Zheng, L., Zhang, Z *et al.*, 2015. A c(RGDfE) conjugated multi-functional nanomedicine delivery system for targeted pancreatic cancer therapy. *J. Mater. Chem. B* 3: 1049–1058. doi:10.1039/c4tb01402b.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* 71: 209–249. doi:10.3322/caac.21660.
- Szostakowska, M., Trębińska-Stryjewska, A., Grzybowska, E.A., Fabisiiewicz, A., 2019. Resistance to endocrine therapy in breast cancer: molecular mechanisms

- and future goals. *Breast Cancer Res. Treat.* 173: 489–497. doi:10.1007/s10549-018-5023-4.
- Tang, Y., Liu, Y., Xie, Y., Chen, J., Dou, Y., 2020. Apoptosis of A549 cells by small interfering RNA targeting survivin delivery using poly- β -amino ester/guanidinylated O-carboxymethyl chitosan nanoparticles. *Asian J. Pharm. Sci.* 15: 121–128. doi:10.1016/j.ajps.2018.09.009.
- Thammaiah, C.K., Jayaram, S., 2016. Role of let-7 family microRNA in breast cancer. *Non-coding RNA Res.* 1: 77–82. doi:10.1016/j.ncrna.2016.10.003.
- Tiğli Aydın, R.S., Pulat, M., 2012. 5-fluorouracil encapsulated chitosan nanoparticles for pH-stimulated drug delivery: Evaluation of controlled release kinetics. *J. Nanomater.* 2012. doi:10.1155/2012/313961.
- Tolosa, L., Donato, M.T., Gómez-Lechón, M.J., 2015. General Cytotoxicity Assessment by Means of the MTT Assay, in: *Protocols in In Vitro Hepatocyte Research*. hal. 333–348. doi:10.1007/978-1-4939-2074-7_26.
- Treiber, T., Treiber, N., Meister, G., 2019. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. *Nat. Rev. Mol. Cell Biol.* 20: 5–20. doi:10.1038/s41580-018-0059-1.
- van Schooneveld, E., Wildiers, H., Vergote, I., Vermeulen, P.B., Dirix, L.Y., Van Laere, S.J., 2015. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. *Breast Cancer Res.* 17: 1–15. doi:10.1186/s13058-015-0526-y.
- Wang, L., Yuan, C., Lv, K., Xie, S., Fu, P., Liu, X., Chen, Y *et al.*, 2013. Lin28 Mediates Radiation Resistance of Breast Cancer Cells via Regulation of Caspase, H2A.X and Let-7 Signaling. *PLoS One* 8: 6–11. doi:10.1371/journal.pone.0067373.
- Wang, Y., Li, J., Guo, S., Ouyang, Y., Yin, L., Liu, S., Zhao, Z *et al.*, 2017. Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma. *Oncotarget* 8: 60414–60428. doi:10.18632/oncotarget.19578.
- Wong, J.S., Cheah, Y.K., 2020. Potential mirnas for mirna-based therapeutics in breast cancer. *Non-coding RNA* 6: 1–39. doi:10.3390/ncrna6030029.
- Wong, T.S., Man, O.Y., Tsang, C.M., Tsao, S.W., Tsang, R.K.Y., Chan, J.Y.W., Ho, W.K *et al.*, 2011. MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. *J. Cancer Res. Clin. Oncol.* 137: 415–422. doi:10.1007/s00432-010-0898-4.
- Wu, L., Zheng, K., Yan, C., Pan, X., Liu, Y., Liu, J., Wang, F *et al.*, 2019. Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma. *BMC Cancer* 19: 1–11. doi:10.1186/s12885-019-6037-y.
- Xu, J., Sun, J., Ho, P.Y., Luo, Z., Ma, W., Zhao, W., Rathod, S.B *et al.*, 2019. Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. *Biomaterials* 210: 25–40. doi:10.1016/j.biomaterials.2019.04.025.
- Xu, X., Zhang, M., Xu, F., Jiang, S., 2020. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. *Mol. Cancer* 19: 1–35. doi:10.1186/s12943-020-01276-5.
- Yin, P., Wang, W., Zhang, Z., Bai, Y., Gao, J., Zhao, C., 2018. Wnt signaling in

- human and mouse breast cancer: Focusing on Wnt ligands, receptors and antagonists. *Cancer Sci.* 109: 3368–3375. doi:10.1111/cas.13771.
- Ysrafil, Y., Astuti, I., Anwar, S.L., Martien, R., Sumadi, F.A.N., Wardhana, T., Haryana, S.M., 2020. MicroRNA-155-5p diminishes in vitro ovarian cancer cell viability by targeting HIF1 α expression. *Adv. Pharm. Bull.* 10: 630–637. doi:10.34172/apb.2020.076.
- Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y *et al.*, 2007. let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. *Cell* 131: 1109–1123. doi:10.1016/j.cell.2007.10.054.
- Yu, S., Kim, T., Yoo, K.H., Kang, K., 2017. The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer. *Biochem. Biophys. Res. Commun.* 486: 752–758. doi:10.1016/j.bbrc.2017.03.114.
- Zhang, J., Zhou, L., Nan, Z., Yuan, Q., Wen, J., Xu, M., Li, Y *et al.*, 2017. Knockdown of c-Myc activates Fas-mediated apoptosis and sensitizes A549 cells to radiation. *Oncol. Rep.* 38: 2471–2479. doi:10.3892/or.2017.5897.
- Zhang, Y., 2017. Ganoderma lucidum (Reishi) suppresses proliferation and migration of breast cancer cells via inhibiting Wnt/ β -catenin signaling. *Biochem. Biophys. Res. Commun.* 488: 679–684. doi:10.1016/j.bbrc.2017.04.086.
- Zografos, E., Zagouri, F., Kalapanida, D., Zakopoulou, R., Kyriazoglou, A., Apostolidou, K., Gazouli, M *et al.*, 2019. Prognostic role of microRNAs in breast cancer: A systematic review. *Oncotarget* 10: 7156–7178. doi:10.18632/oncotarget.27327.